Expression of androgen receptor splice variants in clinical breast cancers

Citations Over TimeTop 10% of 2015 papers

Abstract

The importance of androgen receptor (AR) signaling is increasingly being recognized in breast cancer, which has elicited clinical trials aimed at assessing the efficacy of androgen deprivation therapy (ADT) for metastatic disease. In prostate cancer, resistance to ADT is frequently associated with the emergence of androgen-independent splice variants of the AR (AR variants, AR-Vs) that lack the LBD and are constitutively active. Women with breast cancer may be prone to a similar phenomenon. Herein, we show that in addition to the prototypical transcript, the AR gene produces a diverse range of AR-V transcripts in primary breast tumors. The most frequently and highly expressed variant was AR-V7 (exons 1/2/3/CE3), which was detectable at the mRNA level in > 50% of all breast cancers and at the protein level in a subset of ERα-negative tumors. Functionally, AR-V7 is a constitutively active and ADT-resistant transcription factor that promotes growth and regulates a transcriptional program distinct from AR in ERα-negative breast cancer cells. Importantly, we provide ex vivo evidence that AR-V7 is upregulated by the AR antagonist enzalutamide in primary breast tumors. These findings have implications for treatment response in the ongoing clinical trials of ADT in breast cancer.

Related Papers

• → Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy(2014)192 cited
• → Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide(2016)11 cited
• → PD59-11 TARGETING BCL2 TO INCREASE ENZALUTAMIDE SENSITIVITY TO BETTER SUPPRESS PROSTATE CANCER PROGRESSION THROUGH ALTERING ARV7 PROTEIN DEGRADATION(2020)
• → Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide(2020)
• → Modern antiandrogenic therapy of patients with castration-resistant prostate cancer without metastases(2020)